The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate
Abstract
Mood stabilizing drugs lithium and valproate are the most commonly used treatments for bipolar disorder. Previous studies in our laboratory indicate that chronic treatment with lithium and valproate inhibits oxidative damage in primary cultured rat cerebral cortical cells. Glutathione, as the major antioxidant in the brain, plays a key role in defending against oxidative damage. The purpose of this study was to determine the role of glutathione in the neuroprotective effects of lithium and valproate against oxidative damage. We found that chronic treatment with lithium and valproate inhibited reactive oxygen metabolite H(2)O(2)-induced cell death in primary cultured rat cerebral cortical cells, while buthionine sulfoximine, an inhibitor of glutathione rate-limiting synthesis enzyme glutamate-cysteine ligase, reduced the neuroprotective effect of lithium and valproate against H(2)O(2)-induced cell death. Further, we found that chronic treatment with lithium and valproate increased glutathione levels in primary cultured rat cerebral cortical cells and that the effects of lithium and valproate on glutathione levels were dose-dependent in human neuroblastoma SH-SY5Y cells. Chronic treatment with lithium and valproate also increased the expression of glutamate-cysteine ligase in both rat cerebral cortical cells and SH-SY5Y cells. In addition, chronic treatment with other mood stabilizing drugs lamotrigine and carbamazepine, but not antidepressants desipramine and fluoxetine, increased both glutathione levels and the expression of glutamate-cysteine ligase in SH-SY5Y cells. These results suggest that glutathione plays an important role in the neuroprotective effects of lithium and valproate, and that glutathione may be a common target for mood stabilizing drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, consistent evidences are showing that the inhibition of oxidative damaging processes provoked by injuries to rat cerebral cortical cells by the chronic treatment with lithium is remarkably efficient [259].”
From Oxidative Stress Implications in the Affective Disorders: Main Biomarkers, Animal Models Relevance, Genetic Perspectives, and Antioxidant Approaches (2016) · cites this paper as [259]
Citations
Cites
Tietze, F. (1969) · Analytical Biochemistry · doi:10.1016/0003-2697(69)90064-5 · Cited by 6,077
Hayes, J. D., Flanagan, J. U., & Jowsey, I. R. (2004) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095857 · Cited by 3,565
Mitochondrial diseases in man and mouse
Wallace, D. C. (1999) · Science · doi:10.1126/science.283.5407.1482 · Cited by 3,060
Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species
Kane, D. J., Sarafian, T. A., Anton, R., Hahn, H., Gralla, E. B., Valentine, J. S., Örd, T., & Bredesen, D. E. (1993) · Science · doi:10.1126/science.8235659 · Cited by 1,671
Biologic and pharmacologic regulation of mammalian glutathione synthesis
Griffith, O. W. (1999) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(99)00176-8 · Cited by 1,210
Glutathione S-Transferase Polymorphisms and Their Biological Consequences
Hayes, J. D., & Strange, R. C. (2000) · Pharmacology · doi:10.1159/000028396 · Cited by 997
Frontal lobe and cognitive development
Fuster, J. M. (2002) · Journal of Neurocytology · doi:10.1023/a:1024190429920 · Cited by 916
Glutathione Pathways in the Brain
Dringen, R., & Hirrlinger, J. (2003) · Biological Chemistry · doi:10.1515/bc.2003.059 · Cited by 597
Textbook of psychopharmacology
Edwards, G. (1975) · Nature · doi:10.1038/258648b0 · Cited by 583
Rajkowska, G., Halaris, A. E., & Selemon, L. D. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01080-0 · Cited by 572
Cited by
Sorted by citations
Berk, M., Kapczinski, F., Andreazza, A. C., Dean, O. M., Giorlando, F., Maes, M., Yücel, M., Gama, C. S., Dodd, S., Dean, B., et al. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.10.001 · Cited by 1,178
Oxidative stress in psychiatric disorders: evidence base and therapeutic implications
Ng, F., Berk, M., Dean, O., & Bush, A. I. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008401 · Cited by 1,069
Gawryluk, J. W., Wang, J.-F., Andreazza, A. C., Shao, L., & Young, L. T. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000805 · Cited by 594
Self-citationImpaired mitochondrial function in psychiatric disorders
Manji, H. K., Kato, T., Prospero, N. A. D., Ness, S. L., Beal, M. F., Krams, M., & Chen, G. (2012) · Nature reviews. Neuroscience · doi:10.1038/nrn3229 · Cited by 493
Mitochondrial Dysfunction and Psychiatric Disorders
Rezin, G. T., Amboni, G., Zugno, A. I., Quevedo, J., & STRECK, E. L. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9865-8 · Cited by 453
Metadata
- Authors
- Cui, J., Shao, L., Young, L. T., & Wang, J.-F.
- Affiliations
- Centre for Addiction and Mental Health (CA)
- Corresponding author
- Wang, J.-F.
- Venue
- Neuroscience
- Publisher
- Elsevier BV
- Published
- 2007-02
- Volume
- 144
- Issue
- 4
- Pages
- 1447-1453
- ISSN
- 0306-4522 (ISSN-L)
- OpenAlex
- W2085156996
- Cited by
- 160
- References
- 54
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 3 · 2022: 5 · 2021: 6 · 2020: 5 · 2019: 7 · 2018: 7 · 2017: 7 · 2016: 5 · 2015: 11 · 2014: 13 · 2013: 9 · 2012: 20
- FWCI
- 7.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glutathione Transferases and Polymorphisms
- Health Sciences › Medicine › Biochemistry (medical) › Antioxidant Activity and Oxidative Stress
- Keywords
- glutathione, neuroprotection, mood stabilizers, lithium, valproic acid, bipolar disorder, oxidative stress, gamma-glutamylcysteine synthetase, buthionine sulfoximine, hydrogen peroxide-induced cell death, SH-SY5Y cells, lamotrigine, carbamazepine, glutathione synthesis
- MeSH terms
- Lamotrigine, Animals, Brain, Carbamazepine, Cells, Cultured, Cerebral Cortex, Enzyme Inhibitors, Glutamate-Cysteine Ligase, Glutathione, Humans, Lithium, Nerve Degeneration, Neurons, Triazines, Valproic Acid, Cell Death, Rats, Sprague-Dawley, Reactive Oxygen Species, Oxidative Stress, Antimanic Agents, Neuroprotective Agents, Cell Line, Tumor, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
